Wire Stories

Asia Pacific Spintronics Market Report to 2031: Players Include Avalanche Technology, Crocus Technology, Everspin Technologies, IBM and Intel – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Asia Pacific Spintronics Market 2021-2031 by Device Type, Application, Industry Vertical, and Country: Trend Forecast and Growth Opportunity"…

4 years ago

Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy

TOKYO--(BUSINESS WIRE)--Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to…

4 years ago

Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy

TOKYO--(BUSINESS WIRE)--Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to…

4 years ago

Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy

TOKYO--(BUSINESS WIRE)--Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to…

4 years ago

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors

GUANGZHOU, China--(BUSINESS WIRE)--#ADC--Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase…

4 years ago

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors

GUANGZHOU, China--(BUSINESS WIRE)--#ADC--Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase…

4 years ago

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors

GUANGZHOU, China--(BUSINESS WIRE)--#ADC--Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase…

4 years ago

Biocytogen Announces RenLite™ Licensing Agreement with Janssen

BEIJING--(BUSINESS WIRE)--#Antibody--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen…

4 years ago

Biocytogen Announces RenLite™ Licensing Agreement with Janssen

BEIJING--(BUSINESS WIRE)--#Antibody--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen…

4 years ago

Biocytogen Announces RenLite™ Licensing Agreement with Janssen

BEIJING--(BUSINESS WIRE)--#Antibody--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen…

4 years ago
Show more Posts
Show previous Posts

Search